PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; Pharmacodynamics
- Acronyms PARADIGHM
- Sponsors Shire; Takeda
- 21 Nov 2018 Planned End Date changed from 30 Jun 2035 to 30 Nov 2034.
- 21 Nov 2018 Planned primary completion date changed from 30 Jun 2035 to 30 Nov 2034.
- 22 May 2018 Study design presented at the 20th European Congress of Endocrinology (ECE 2018), according to a Shire plc media release.